A Arkansas overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
38.9% of Arkansas adults have obesity, per the CDC's 2024 BRFSS data 1 — tied with Alabama for the 4th-highest rate among all U.S. states reporting that year, trailing only West Virginia (41.4%), Mississippi (40.4%), and Louisiana (39.2%) 1.
Across 3,088,354 residents 2, what determines access here is a fee-for-service drug list that has no anti-obesity class in it at all.
No. Arkansas Medicaid does not cover GLP-1s for weight loss — its Preferred Drug List keeps every GLP-1 receptor agonist strictly inside the Antidiabetic Agents class, with no Anti-Obesity/Weight-Loss Agents class anywhere in the document 3.
Point-of-sale coverage requires a billed type 2 diabetes diagnosis plus a metformin claim within the last 186 days, an HbA1c of 9 or higher within the last 186 days, or a billed ASCVD diagnosis (or, alternatively, a paid GLP-1 claim in the last 60 days) 4. Trulicity and Victoza are preferred; Ozempic and Mounjaro are non-preferred and require prior authorization under the same diabetes-only criteria 3.
Wegovy and Zepbound do exist elsewhere in the PBM's Clinical Criteria manual, but only for non-obesity uses — Wegovy for reducing cardiovascular-event risk in patients with established heart disease, Zepbound for obstructive sleep apnea — and both sections state plainly that Arkansas Medicaid does not cover the drugs solely for weight loss 4. The state's ARHOME Medicaid-expansion program (Section 1115), run by the same DHS division, does not change any of this 7: no obesity or weight-management indication is covered for any GLP-1 in Arkansas.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Arkansas's uninsured rate is 9.4% and median household income is $62,106 (ACS 2024 1-year estimates) 8 — the lowest-income context of any state in this pack, which is exactly why the price is published rather than quoted per market. Local clinic price checks live on the Fayetteville and Little Rock pages below, not here.
HRSA lists 148 currently-Designated Primary Care Health Professional Shortage Areas in Arkansas (of 744 total historical Arkansas records in HRSA's file, most now Withdrawn) 6. For much of the state, seeing an obesity-medicine or endocrinology specialist means a drive measured in counties, not blocks.
A telehealth visit removes the distance requirement entirely: evaluation, prescription, and dose management happen from home, on the same schedule as an in-person program.
Physicians treating Arkansas residents are licensed by the Arkansas State Medical Board. This page does not state a specific Arkansas telehealth statute or rule number: the board's telehealth-prescribing rule was not verified in this research pass, and no board URL was confirmed. Consult your state medical board's telehealth regulations for current requirements.
Astra is licensed in all 50 states, including Arkansas. There is no waitlist tied to where in the state you live.
Astra treats patients in Arkansas through state-licensed physicians.
Fayetteville and Little Rock each have their own page with city-level obesity data and a check of local clinic pricing where providers publish it.
No. Arkansas Medicaid's Preferred Drug List keeps GLP-1 receptor agonists strictly in the Antidiabetic Agents class — coverage requires a billed type 2 diabetes diagnosis (plus a metformin claim, high HbA1c, or ASCVD diagnosis, or a recent GLP-1 claim). Wegovy and Zepbound do appear in Arkansas Medicaid's Clinical Criteria manual, but only for cardiovascular-risk reduction and obstructive sleep apnea respectively — both sections state the program does not cover the drugs solely for weight loss. Arkansas's ARHOME Medicaid expansion doesn't change this.
No — and that's by design. Astra charges the same $68/month for semaglutide and $118/month for tirzepatide (12-month plans, $816/$1,416 billed annually) in Little Rock, Fayetteville, and every other city in the country. There's no city or state markup.
Arkansas's adult obesity rate was 38.9% in 2024 (CDC BRFSS), tying Alabama for the 4th-highest rate among states reporting that year, behind only West Virginia, Mississippi, and Louisiana.
Yes. Astra is licensed in all 50 states, including Arkansas. HRSA lists 148 Designated Primary Care Health Professional Shortage Areas statewide, meaning many Arkansans already drive long distances for in-person specialist care — telehealth removes that distance requirement entirely.
Fayetteville and Little Rock each have their own dedicated page with city-level obesity data and a check of local clinic pricing where it is publicly published.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.